Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer

Published: 5 June 2019
Lung cancer
The aims of treatment are to prolong survival and improve quality of life

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer, informed by a report produced by SHTAC.

NICE’s guidance recommends Atezolizumab plus bevacizumab, carboplatin and paclitaxel as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults:


  • who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or
  • when targeted therapy for epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive NSCLC has failed.

It is recommended only if:

  • atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and
  • the company provides atezolizumab and bevacizumab according to the commercial arrangements.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.


Privacy Settings